Genome & Company is a series c plus startup based in United States. 1 investor tracked. Status: ipo.
Based in the United States, Genome & Company is a startup. Its most recent tracked round is Series-c-plus. Brouky records 1 investor associated with the company.
Genome & Company is a clinical-stage biotechnology company that develops microbiome-based pharmaceuticals and novel immune checkpoint inhibitors, focusing on immuno-oncology, with an expanding focus on antibody-drug conjugates (ADCs) and microbiome cosmetics.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.